[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100591588":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":10,"centralContacts":23,"locations":29,"responsibleParty":43,"collaborators":10,"id":47,"slug":10,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":48,"sex":54,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":10,"studyType":60,"phases":10,"briefSummary":61,"conditions":62,"keywords":10,"overallStatus":66,"whyStopped":10,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Medical College of Wisconsin","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Without GLP-1 RA treatment",null,"Patients with MASLD and obesity\u002Fdiabetes - on standard of care treatment but not on any GLP-1 RA",{"label":13,"type":10,"description":14,"interventionNames":15},"Had GLP-1 RA treatment","Patients with MASLD and obesity\u002Fdiabetes - on GLP-1 RA as a standard of care treatment",[16],"Drug: GLP-1 receptor agonist",[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"DRUG","GLP-1 receptor agonist","on and not on treatment",[13],[24],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"Achuthan Sourianarayanane, MD","CONTACT","4149556850","asourianar@mcw.edu",[30],{"facility":31,"status":10,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":10},"Froedtert Hospital","Milwaukee","Wisconsin","53226","United States","US",{"type":38,"coordinates":39},"Point",[40,41],-87.90647,43.0389,{"lat":41,"lon":40},{"type":44,"investigatorFullName":45,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Achuthan Sourianarayanane","Associate Professor","100591588",false,"NCT06982378","GLP-1 RA on Liver OMICS in MASLD","Effect of Glucagon-like Peptide -1 Receptor Agonist on Liver Tissue and Plasma Lipids in MASLD","OMICS in MASLD","Inclusion Criteria:\n\n* known diagnosis of MASLD by histology, also have diabetes\u002F obesity\n* on treatment with GLP-1 RA at stable dose\n\nExclusion Criteria:\n\n* unable to have a liver biopsy, recent change in medication for diabetes or hyperlipidemia\n* on immunosuppression, liver or kidney transplant\n* pregnancy","ALL","18 Years","80 Years",{"count":58,"type":59},30,"ESTIMATED","OBSERVATIONAL","In patients with type II diabetes mellitus (T2DM) and obesity, an excess plasma-free fatty acid is found with an associated increased lipid accumulation in adipocytes and liver tissue. Lipid droplet accumulation in the hepatocytes is an initial step in the development of metabolic dysfunction associated steatotic liver disease (MASLD. Insulin resistance, which is associated with T2DM, mediates the inflammation of these lipids, resulting in the progression of MASLD to metabolic dysfunction associated steatotic hepatitis (MASH). Hence, in T2DM, obesity, and MASLD, changes in the lipid profile occur, and they are interrelated.\n\nIn this study, we aim to assess improvement in the lipidomic, its associated metabolic changes and evaluate the co-regulated genes in the liver tissue among patients with MASLD with intervention with GLP-1 RA, which has shown to benefit T2DM and obesity.",[63,64,65],"NAFLD","Diabetes","Obesity","NOT_YET_RECRUITING","2026-03-08",{"date":69,"type":70},"2026-03-10","ACTUAL",{"date":72,"type":59},"2026-07",{"date":74,"type":59},"2028-12",{"name":5,"class":6},1]